respiratori
monitor
measur
lung
volum
alway
concern
patient
receiv
mechan
ventil
mv
complex
method
propos
clinic
investig
patron
et
al
describ
simplifi
helium
dilut
techniqu
measur
endexpiratori
lung
volum
compar
comput
tomographi
ct
mv
patient
author
specif
studi
accuraci
precis
method
simpl
rebreath
ga
use
deliv
least
ten
usual
tidal
volum
agreement
two
method
found
accept
clinic
purpos
note
howev
higher
amount
hyperinfl
tissu
greater
underestim
lung
volum
helium
dilut
method
well
demonstr
frequent
caus
repeat
lung
volum
loss
endotrach
suction
induc
derecruit
patient
acut
respiratori
distress
syndrom
ard
effect
maneuv
test
ten
patient
mild
moder
lung
failur
fernandez
et
al
three
techniqu
compar
without
preoxygen
author
found
reduct
lung
volum
suction
similar
quasiclos
close
system
significantli
higher
open
system
also
observ
patient
without
sever
lung
diseas
chang
transient
rapidli
revers
within
min
alveolar
consolid
best
diagnos
ct
lichtenstein
et
al
continu
assess
use
lung
ultrasound
examin
icu
assess
valu
patient
ct
confirm
alveolar
consolid
diagnos
ultrasound
convers
ultrasound
posit
one
control
patient
without
alveolar
consolid
ct
least
author
hand
techniqu
seem
constitut
reliabl
tool
diagnosi
measur
respiratori
mechan
usual
describ
respiratori
system
term
elast
complianc
time
constant
eleg
studi
kondili
et
al
divid
tidal
expir
differ
phase
base
analysi
expiratori
flowvolum
curv
ten
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
show
end
expir
character
lengthen
time
constant
addit
extern
posit
endexpiratori
pressur
decreas
resist
end
expir
shorten
time
constant
thu
facilit
equilibr
extern
pressur
alveolar
pressur
although
alreadi
knew
effect
extern
posit
endexpiratori
pressur
patient
new
method
explor
shed
new
light
mechan
part
expiratori
resist
caus
endotrach
tube
mani
case
contribut
huge
howev
studi
suggest
cours
mv
inner
diamet
tube
may
progress
decreas
due
perman
deposit
secret
use
acoust
reflectometri
method
et
al
prospect
assess
inner
volum
reduct
endotrach
tube
use
patient
found
reduct
extrem
frequent
almost
onefourth
patient
real
diamet
tube
smaller
mm
clinic
implic
find
may
import
studi
need
topic
intraabdomin
hypertens
may
import
clinic
consequ
term
respiratori
function
intraabdomin
organ
function
preval
howev
known
thu
great
merit
multicent
collabor
preval
studi
malbrain
et
al
icu
six
countri
evalu
frequenc
cohort
patient
base
definit
abnorm
intraabdomin
pressur
mmhg
higher
preval
patient
abdomin
compart
syndrom
pressur
mmhg
higher
risk
factor
bodi
mass
index
effect
massiv
fluid
resuscit
renal
coagul
impair
limit
statist
signific
last
intrahospit
transport
pose
import
risk
icu
patient
continu
monitor
well
presenc
qualifi
staff
well
maintain
equip
probabl
essenti
minim
incid
australian
incid
monitor
studi
intens
care
receiv
report
describ
incid
period
tri
identifi
contribut
factor
systembas
other
humanbas
incid
signific
advers
outcom
number
factor
also
identifi
prevent
limit
harm
problem
often
underestim
underreport
deserv
great
attent
editori
shirley
bion
accompani
paper
acut
respiratori
distress
syndrom
epidemiolog
characterist
outcom
acut
lung
injuri
ali
vari
across
studi
variabl
depend
definit
subpopul
includ
studi
comorbid
sever
diseas
per
se
brunbuisson
cowork
studi
current
occurr
caus
ali
ard
relationship
respect
outcom
mild
ali
pao
mmhg
ard
pao
fio
equal
mmhg
factor
associ
surviv
incept
cohort
februarymarch
individu
ali
among
patient
admit
least
h
intens
care
unit
icu
scrutin
data
pertain
ten
european
countri
icu
among
patient
initi
mild
ali
went
ard
mild
ali
ard
crude
icu
hospit
mortal
rate
p
mild
ali
ard
initi
mean
tidal
volum
posit
endexpiratori
pressur
mlkg
cmh
ard
patient
air
leak
detect
subject
multivari
analysi
mortal
associ
age
immunoincompet
simplifi
acut
physiolog
score
sap
ii
logist
organ
dysfunct
score
earli
air
leak
author
conclud
ali
frequent
continuum
ali
ard
substanti
differ
mortal
much
higher
ard
editori
comment
rubenfeld
christi
accompani
articl
also
erratum
pao
ratio
mmhg
one
diagnost
criteria
ard
accord
americaneuropean
consensu
confer
yet
ratio
affect
number
factor
ventil
set
fio
per
se
ferguson
colleagu
analyz
impact
enrol
trial
highfrequ
oscillatori
ventil
potenti
effect
studi
outcom
screen
ard
patient
place
standard
ventil
set
set
pressur
control
ventil
achiev
tidal
volum
mlkg
predict
bodi
weight
ensur
peak
inspiratori
pressur
cmh
fio
posit
endexpiratori
pressur
cmh
fortyon
consecut
patient
includ
institut
standard
set
patient
pao
fio
persist
mmhg
remaind
patient
pao
fio
mmhg
min
chang
implement
chang
fio
main
reason
chang
pao
fio
icu
mortal
rate
significantli
greater
persist
ard
transient
form
vs
respect
author
conclud
find
import
trial
design
observ
differ
outcom
propos
use
standard
ventil
set
patient
enrol
china
seen
enorm
econom
growth
yet
countri
demograph
characterist
differ
substanti
western
world
epidemiolog
characterist
ard
china
larg
unknown
lu
cowork
perform
survey
icu
univers
hospit
shanghai
aim
investig
incid
caus
outcom
ard
adult
patient
treat
icu
least
h
total
admiss
regist
period
patient
diagnos
ard
common
predispos
factor
ard
pneumonia
sepsi
nonpulmonari
origin
twentyseven
patient
intub
receiv
invas
mv
frequent
use
ventilatori
mode
synchron
intermitt
mandatori
ventil
hospit
mortal
rate
ard
patient
major
ard
patient
die
multipl
organ
dysfunct
wherea
die
refractori
respiratori
failur
author
conclud
reassess
respiratori
intens
care
manag
implement
effect
therapeut
intervent
requir
sever
acut
respiratori
syndrom
sever
acut
respiratori
syndrom
epidem
whose
caus
agent
coronaviru
carri
mortal
rate
young
patient
elderli
gomersal
cowork
undertook
retrospect
observ
cohort
studi
first
patient
admit
icu
hong
kong
univers
hospit
respiratori
failur
aim
describ
clinic
cours
outcom
patient
investig
factor
associ
prognosi
median
acut
physiolog
chronic
health
evalu
apach
ii
score
interquartil
rang
day
patient
aliv
undergo
mv
receiv
mv
die
seven
ventil
patient
develop
barotrauma
despit
low
tidal
volum
mean
tidal
volum
mlkg
predict
bodi
weight
lowpressur
strategi
mean
posit
endexpiratori
pressur
cmh
peak
airway
pressur
cmh
develop
barotrauma
cmh
develop
variabl
associ
poor
outcom
univari
analysi
age
sever
ill
lymphocyt
count
decreas
steroid
dose
posit
fluid
balanc
chronic
diseas
immunosuppres
nosocomi
sepsi
author
conclud
mortal
high
syndrom
caus
sever
respiratori
failur
littl
organ
failur
high
incid
barotrauma
requir
mv
endotrach
extub
final
step
wean
mv
fail
tracheal
extub
entail
wors
prognosi
tradit
wean
indic
poor
predictor
extub
outcom
data
suggest
patient
neurolog
diagnos
lack
adequ
cough
frequent
endotrach
suction
increas
risk
extub
failur
salam
cowork
object
assess
impact
neurolog
statu
cough
strength
volum
endotrach
secret
extub
outcom
patient
pass
spontan
breath
trial
measur
cough
peak
flow
endotrach
secret
abil
complet
four
simpl
task
open
eye
follow
eye
grasp
hand
stick
tongu
fourteen
patient
fail
first
extub
patient
cough
peak
flow
equal
lmin
like
fail
extub
cough
peak
flow
higher
lmin
risk
ratio
rr
confid
interv
ci
patient
secret
mlh
like
fail
fewer
secret
rr
ci
patient
unabl
complet
task
like
fail
complet
command
rr
ci
presenc
two
risk
factor
sensit
specif
predict
extub
failur
author
conclud
simpl
inexpens
reproduc
method
provid
use
clinic
approach
guid
extub
process
editori
epstein
comment
articl
periextub
pain
receiv
littl
attent
icu
patient
acut
pain
arous
clinic
manifest
relat
sympathet
system
activ
lead
deleteri
cardiovascular
effect
gacouin
cowork
assess
intens
pain
extub
time
use
visual
analogu
scale
total
extub
patient
period
year
pain
significantli
associ
sap
ii
durat
mv
day
intub
perform
oper
room
sever
pain
report
patient
pain
resolv
within
h
extub
major
patient
durat
mv
day
longer
independ
risk
factor
pain
least
moder
intens
odd
ratio
ci
author
conclud
periextub
pain
frequent
consid
treatment
unplan
deliber
selfextub
trachea
may
affect
patient
outcom
clinic
resourc
moon
cowork
develop
risk
assess
tool
categor
patient
risk
deliber
tracheal
selfextub
patient
admit
seven
icu
larg
referr
tertiari
center
intub
h
follow
month
period
case
unplan
extub
occur
clinic
demograph
characterist
compar
randomli
select
control
patient
incid
unplan
extub
densiti
incid
per
ventil
day
incid
lower
surgic
icu
compar
medic
icu
fifteen
case
requir
reintub
multipl
logist
regress
indic
patient
low
sedat
level
higher
degre
conscious
higher
risk
deliber
selfextub
author
conclud
appropri
reduct
sedat
patient
wean
time
extub
increas
surveil
high
risk
recogn
may
reduc
number
unplan
extub
recent
intern
consensu
confer
intens
care
medicin
use
niv
acut
respiratori
failur
clearli
state
addit
nppv
standard
medic
treatment
patient
acut
respiratori
failur
may
prevent
eti
reduc
rate
complic
mortal
patient
hypercapn
pump
failur
concern
episod
lung
failur
document
conclud
use
niv
may
also
appropri
treatment
select
patient
popul
acut
lung
failur
singl
studi
demonstr
noninvas
mv
niv
adequ
altern
convent
ventilatori
support
better
therapeut
strategi
standard
therapi
plu
oxygen
patient
studi
requir
confirm
find
year
four
studi
publish
intens
care
medicin
improv
understand
perhap
expand
indic
niv
highlight
methodolog
problem
continu
posit
airway
pressur
cpap
consid
effect
treatment
acut
respiratori
failur
arf
due
cardiogen
pulmonari
edema
cpe
lher
et
al
compar
physiolog
clinic
effect
cpap
standard
medic
therapi
subset
old
patient
year
applic
form
mv
sometim
deni
within
h
cpap
led
decreas
respiratori
rate
improv
oxygen
compar
baselin
wherea
differ
observ
medic
treatment
group
seventeen
patient
latter
group
develop
sever
complic
vs
four
cpap
group
earli
mortal
significantli
lower
ventil
patient
overal
hospit
mortal
author
conclud
cpap
promot
earli
clinic
physiolog
improv
elderli
patient
episod
arf
due
cpe
without
affect
overal
mortal
niv
consid
first
line
treatment
prevent
intub
copd
patient
episod
hypercapn
arf
littl
known
effect
real
altern
invas
mv
criteria
emerg
intub
met
match
case
control
studi
perform
copd
patient
sever
arf
ph
paco
mmhg
squadron
et
al
evalu
efficaci
noninvas
case
vs
invas
mv
control
mortal
rate
durat
mv
length
icu
hospit
stay
differ
two
group
niv
group
fewer
complic
tendenc
wean
earlier
ventil
intub
rate
case
group
subset
patient
similar
outcom
control
group
success
niv
lower
mortal
rate
shorter
icu
hospit
stay
patient
receiv
intub
copd
patient
advanc
hypercapn
arf
niv
thu
high
rate
failur
nevertheless
provid
advantag
compar
invas
ventil
inde
subgroup
analysi
suggest
delay
intub
deleteri
subset
patient
fail
niv
patient
sever
chronic
pulmonari
diseas
often
suffer
coexist
patholog
also
like
develop
extrapulmonari
complic
scala
cowork
assess
impact
comorbid
shortand
longterm
outcom
niv
hypercapn
arf
copd
patient
patient
ph
paco
mmhg
failur
success
group
accord
whether
niv
avoid
intub
preval
chronic
acut
comorbid
respect
case
cardiovascular
niv
failur
mortal
greater
patient
without
comorbid
multipl
regress
analysi
predict
niv
failur
acut
comorbid
forc
expiratori
volum
death
month
predict
singl
acut
comorbid
noncardiovascular
origin
worst
preexist
activ
daili
live
presenc
comorbid
common
copd
patient
requir
niv
presenc
influenc
outcom
patient
technic
aspect
niv
includ
type
interfac
ventil
ventilatori
mode
employ
also
margin
factor
may
interfer
patient
wellb
clear
exampl
loud
sound
contribut
patient
discomfort
icu
stay
cavalier
et
al
studi
nois
intens
ten
healthi
volunt
undergo
niv
two
differ
level
pressur
support
cmh
use
helmet
without
heat
moistur
exchang
filter
full
face
mask
nasal
mask
insid
helmet
nois
intens
exceed
db
significantli
higher
facial
nasal
ventil
db
nois
intens
affect
level
pressur
appli
presenc
filter
level
discomfort
similar
use
four
differ
set
author
conclud
niv
helmet
associ
significantli
greater
nois
nasal
facial
mask
equal
comfort
shortterm
set
wean
postextub
failur
wean
difficulti
occur
rel
small
percentag
ventil
patient
howev
patient
undergo
prolong
mv
prone
develop
complic
therefor
dramat
increas
cost
care
great
attent
paid
earli
identif
patient
like
fail
wean
predict
may
develop
postextub
respiratori
failur
three
studi
assess
caus
wean
failur
effect
physiolog
indic
predict
wean
postextub
failur
paresi
acquir
icu
stay
icuap
recogn
major
event
often
occur
manag
patient
prolong
critic
ill
also
shown
durat
mv
independ
predictor
icuap
de
jongh
et
al
studi
prospect
cohort
patient
without
preexist
neuromuscular
diseas
ventil
longer
day
determin
whether
icuap
independ
risk
factor
prolong
wean
awaken
presenc
icuap
defin
medic
research
council
score
lower
patient
develop
icuap
significantli
longer
wean
time
day
vs
day
multivari
analysi
two
independ
predictor
prolong
wean
icuap
presenc
copd
author
conclud
icuap
strongest
independ
predictor
prolong
mv
prevent
icuap
result
shorter
wean
time
studi
investig
util
accuraci
wean
indic
blind
conti
cowork
evalu
popular
wean
indic
blind
fashion
ie
physician
make
decis
wean
alway
unawar
predict
valu
studi
two
step
patient
data
first
use
select
cutoff
valu
wean
predictor
ie
minim
fals
classif
valu
prospect
valid
cohort
patient
variabl
record
first
min
discontinu
ventil
vital
capac
tidal
volum
pressur
first
ms
occlud
inspir
minut
ventil
respiratori
rate
maxim
inspiratori
pressur
mip
rapid
shallow
breath
index
fvt
fvt
receiv
oper
characterist
curv
show
test
abil
discrimin
success
failur
author
conclud
common
evalu
indic
poor
predictor
wean
outcom
breath
pattern
normal
person
display
certain
variabl
maintain
central
neural
mechan
feedback
loop
arteri
chemoreceptor
lung
vagal
sensori
receptor
deviat
breath
pattern
variabl
bpv
normal
level
found
individu
patholog
condit
bien
et
al
investig
whether
potenti
chang
bpv
predict
wean
mv
postop
patient
recov
system
inflammatori
respons
syndrom
sir
analysi
employ
assess
bpv
period
pressur
support
ventil
cmh
pointcar
plot
scattergram
dynam
analyz
breath
pattern
realtim
breathtobreath
basi
coeffici
variat
sd
indic
dispers
data
point
plot
significantli
lower
patient
fail
wean
attempt
low
bpv
associ
high
incid
wean
failur
variabl
may
potenti
serv
wean
predictor
propos
predictor
wean
paramet
despit
result
somewhat
controversi
fernandez
cowork
although
catheterrel
infect
cri
rate
decreas
due
improv
infect
control
techniqu
devic
cri
remain
major
caus
nosocomi
bacteremia
icu
prevent
strategi
new
devic
oppos
colon
continu
test
four
random
control
trial
rct
topic
publish
intens
care
medicin
year
langgartn
et
al
examin
central
venou
cathet
cvc
investig
whether
skin
disinfect
cvc
insert
alcohol
plu
chlorhexidin
solut
follow
povidoneiodin
provid
greater
protect
cvc
colon
infect
either
one
antisept
alon
found
cathet
colon
rate
reduc
fivefold
povidoneiodin
alon
success
applic
antisept
molecular
type
organ
confirm
cvc
colon
origin
skin
insert
site
sampl
size
studi
howev
small
confirm
reduct
infect
rate
anoth
rct
includ
cvc
carrasco
et
al
compar
heparinco
triplelumen
cathet
chlorhexidinesulfadiazin
coat
one
comparison
perform
previous
colon
found
heparinco
cathet
chlorhexidin
silver
sulfadiazin
coat
cathet
incid
cvcrelat
bloodstream
infect
bsi
differ
final
brunbuisson
et
al
test
new
gener
antisepticco
cathet
enhanc
chlorhexidinesilv
sulfadiazin
coat
intern
extern
aspect
cvc
vs
nonimpregn
cvc
rct
enrol
patient
signific
colon
cathet
occur
patient
respect
noncoat
coat
group
vs
per
catheterday
cvcrelat
bsi
occur
patient
noncoat
coat
group
respect
vs
per
cathet
day
trial
antimicrobialimpregn
cathet
associ
signific
reduct
cathet
colon
trend
reduct
infect
episod
bsi
noteworthi
trial
rel
low
definit
rate
cvcrelat
bsi
control
group
context
difficult
demonstr
efficaci
antimicrobialimpregn
cathet
unless
sampl
size
studi
adequ
power
potenti
increas
risk
colon
antibioticimpregn
cathet
candida
spp
need
confirmatori
evid
safdar
maki
provid
addit
evid
support
predomin
pathogenesi
shortterm
cvcrelat
infect
analyz
combin
result
two
trial
cathet
test
prevent
strategi
aim
minim
cathet
colon
skin
entri
site
pathogenesi
infect
confirm
dna
type
organ
overal
cvcrelat
bsi
rate
catheterday
pool
control
group
two
trial
cvcrelat
bsi
occur
per
catheterday
infect
extralumin
acquir
intralumin
deriv
indetermin
contrast
cvcrelat
bsi
treatment
group
often
intralumin
deriv
author
conclud
cvcrelat
bsi
extralumin
acquir
deriv
cutan
microflora
therefor
strategi
achiev
success
suppress
cutan
colon
substanti
reduc
risk
cvcrelat
bsi
associ
shortterm
cvc
noteworthi
cvc
remov
suspect
infect
prove
infect
limit
wast
remov
cathet
rijnder
et
al
test
small
rct
whether
watch
wait
strategi
select
patient
low
moder
suspicion
cvc
infect
observ
without
remov
cvc
safe
allow
retain
cvc
hemodynam
stabl
patient
without
proven
bacteremia
insert
site
infect
intravascular
foreign
bodi
random
standardofcar
group
cvc
chang
plan
watch
wait
group
cvc
chang
bacteremia
hemodynam
instabl
subsequ
occur
patient
suspect
cri
patient
met
exclus
criteria
shown
bacterem
includ
cvcrelat
bsi
random
cvc
chang
standard
group
vs
watch
wait
group
reduct
p
differ
bacteremia
rate
outcom
patient
author
conclud
use
simpl
clinic
algorithm
permit
substanti
decreas
number
unnecessarili
remov
cvc
without
increas
morbid
accompani
editori
brunbuisson
emphas
valu
conserv
approach
select
patient
lowmoder
suspicion
cvc
infect
comment
potenti
valu
addit
test
skin
site
insert
swab
cultur
pair
blood
cultur
assist
clinic
decis
make
conserv
approach
identifi
factor
associ
hospit
outcom
adult
patient
infect
endocard
ie
mourvilli
et
al
retrospect
review
patient
admit
period
referr
center
icu
overal
hospit
mortal
rate
patient
nativ
valv
ie
variabl
associ
outcom
multivari
analysi
includ
septic
shock
ci
cerebr
emboli
ci
immunocompromis
state
ci
cardiac
surgeri
ci
prosthet
valv
ie
variabl
includ
septic
shock
ci
neurolog
complic
ci
immunocompromis
state
ci
author
conclud
ie
associ
high
mortal
rate
patient
requir
icu
admiss
although
earli
complic
make
optim
medic
surgic
manag
decis
often
difficult
surgic
treatment
appear
improv
outcom
patient
questionnair
survey
french
intensivist
azoulay
et
al
address
difficult
unresolv
question
interpret
lower
respiratori
secret
sampl
posit
candida
spp
expect
physician
attitud
vari
wide
although
major
felt
posit
sampl
candida
reflect
colon
nonimmunocompromis
patient
onefourth
inclin
provid
antifung
therapi
major
felt
repeat
sampl
variou
site
calcul
colon
index
necessari
author
conclud
addit
studi
need
improv
understand
respiratori
tract
candida
colon
infect
nonneutropen
mv
patient
determin
indic
preemptiv
antifung
therapi
popul
misset
et
al
report
result
infect
control
qualiti
improv
program
base
publish
guidelin
reduc
nosocomi
infect
rate
medicalsurg
icu
mean
devicerel
infect
rate
per
procedureday
ventilatorassoci
pneumonia
vap
urinari
tract
infect
uti
cvc
colon
cvcrelat
bsi
studi
period
signific
declin
uti
cvcrelat
infect
rate
increas
time
infect
vap
rate
author
conclud
uti
cvcrelat
infect
reduc
continu
qualityimprov
program
base
surveil
nosocomi
infect
identifi
factor
associ
high
use
antimicrobi
meyer
et
al
report
result
first
year
icu
sari
program
surveil
system
antimicrobi
use
german
icu
network
set
mean
antimicrobi
use
densiti
ad
patientday
correl
length
stay
penicillin
plu
blactamas
inhibitor
ad
quinolon
antimicrobi
use
length
stay
independ
risk
factor
ad
percentil
total
amount
antimicrobi
use
per
day
well
higher
use
carbapenem
per
day
extendedspectrum
penicillin
per
day
high
use
glycopeptid
quinolon
ad
percentil
correl
cvc
author
suggest
sari
data
could
serv
benchmark
improv
qualiti
antimicrobi
drug
administr
icu
intern
comparison
two
larg
epidemiolog
studi
sever
sepsi
syndrom
publish
year
provid
updat
epidemiolog
sever
sepsi
brunbuisson
et
al
report
result
incept
cohort
studi
sever
sepsi
shock
conduct
randomli
select
french
icu
patient
admit
sever
sepsi
shock
case
icu
acquir
median
sap
ii
sequenti
organ
failur
assess
sofa
onset
sever
sepsi
respect
mortal
day
sepsi
patient
remain
hospit
month
chronic
liver
heart
failur
acut
renal
failur
shock
sap
ii
onset
sever
sepsi
total
sofa
score
independ
risk
factor
strongli
associ
death
author
conclud
wherea
attack
rate
sever
sepsi
increas
french
icu
past
decad
mortal
appear
decreas
suggest
improv
manag
patient
finfer
et
al
report
prospect
populationbas
incept
cohort
incid
studi
conduct
multidisciplinari
icu
hospit
australia
new
zealand
includ
consecut
icu
admiss
total
ci
per
icu
admissionshad
episod
sever
sepsi
icu
mortal
rate
respect
patient
die
hospit
author
estim
incid
sever
sepsi
adult
treat
australian
new
zealand
icu
per
inhabit
conclud
popul
incid
found
prospect
studi
fall
lower
rang
recent
estim
retrospect
studi
unit
state
unit
kingdom
accompani
editori
moss
highlight
question
concern
interpret
epidemiolog
survey
recent
chang
epidemiolog
sepsi
finkielman
et
al
report
singlecent
retrospect
studi
patient
mean
age
year
septic
abort
rel
rare
condit
nowaday
apach
ii
mean
score
admiss
acut
renal
failur
develop
patient
dissemin
intravascular
coagul
septic
shock
blood
cultur
posit
twelv
patient
die
author
conclud
requir
icu
admiss
prevent
event
remain
associ
high
morbid
mortal
diagnost
valu
creactiv
protein
remain
controversi
sierra
et
al
reexamin
question
prospect
observ
studi
patient
sir
subsequ
confirm
without
confirm
infect
normal
control
subject
median
creactiv
protein
valu
day
lower
healthi
subject
mgdl
ci
patient
acut
myocardi
infarct
mgdl
ci
noninfecti
sir
mgdl
ci
sepsi
ci
p
creactiv
protein
threshold
valu
mgdl
sensit
specif
predict
sepsi
author
conclud
determin
serum
creactiv
protein
use
earli
indic
infect
patient
sir
determin
clinic
impact
recent
avail
highli
activ
antiretrovir
therapi
haart
icu
admiss
outcom
patient
infect
human
immunodefici
viru
hiv
vincent
et
al
compar
patient
admit
prehaart
era
haart
era
latter
patient
admit
icu
littl
benefit
avail
haart
histori
antiretrovir
therapi
fail
respond
antiretrovir
icu
admiss
rate
hospit
hivinfect
patient
increas
rather
decreas
compar
prehaart
era
haart
vs
prehaart
adjust
signific
prognost
covari
icu
surviv
unchang
two
period
adjust
ci
surviv
improv
adjust
ci
author
conclud
icu
admiss
rate
hivinfect
patient
remain
high
haart
era
possibl
underutil
therapi
limit
access
health
care
indic
yu
singh
studi
publish
peerreview
journal
past
year
deal
manag
ventilatorassoci
pneumonia
vap
howev
consensu
exist
date
best
way
identifi
patient
true
lung
infect
select
earli
appropri
antimicrobi
therapi
avoid
unnecessari
use
antibiot
controversi
regard
manag
patient
suspect
develop
vap
nourish
numer
studi
compar
differ
bacteriolog
diagnost
techniqu
clinic
bacteriolog
evalu
andor
evalu
clinic
pulmonari
infect
score
cpi
recent
propos
first
step
clinic
strategi
elatr
et
al
conduct
prospect
studi
patient
clinic
suspect
episod
vap
compar
quantit
cultur
endotrach
aspir
eta
plug
telescop
cathet
pneumonia
diagnos
posit
cultur
cfuml
latter
author
report
good
correl
two
techniqu
identifi
bacteri
speci
differenti
posit
neg
cultur
plug
telescop
cathet
use
diagnost
threshold
eta
cfuml
calcul
sensit
specif
eta
usual
wide
use
threshold
cfuml
eta
result
less
good
poor
agreement
two
techniqu
author
conclud
eta
quantit
cultur
adequ
techniqu
identifi
pathogen
organ
signific
concentr
lower
respiratori
tract
diagnos
vap
sinc
quantit
cultur
plug
telescop
cathet
gold
standard
even
silver
standard
differenti
lung
infect
heavi
colon
lower
respiratori
tract
mentec
et
al
report
result
multicent
prospect
studi
conduct
five
french
icu
enrol
patient
suspect
vap
includ
confirm
vap
base
classif
intern
consensu
confer
clinic
investig
vap
four
diagnost
techniqu
compar
blind
tracheal
aspir
blind
protect
telescop
cathet
blind
ptc
bronchoscop
ptc
bronchoscop
bronchoalveolar
lavag
bal
author
found
direct
examin
secret
obtain
blind
ptc
bronchoscop
ptc
bal
similar
valu
diagnos
vap
choos
appropri
initi
treatment
contrast
underlin
blind
bronchoscop
ptc
diagnost
valu
compar
report
bal
collect
sampl
contain
visibl
secret
entir
popul
area
receiv
oper
characterist
curv
signific
smaller
three
techniqu
blind
tracheal
aspir
blind
ptc
bonchoscop
ptc
bal
two
studi
usual
limit
studi
evalu
new
diagnost
method
absenc
clear
definit
definit
diseas
absenc
gold
standard
sever
publish
studi
tri
determin
gold
standardexperiment
studi
anim
studi
postmortem
studi
suggest
combin
histolog
examin
quantit
cultur
lung
tissu
give
argument
strong
enough
valid
elimin
diagnosi
pneumonia
patient
treat
mv
day
dupont
et
al
design
studi
patient
vap
assess
impact
durat
mv
use
antibiot
treatment
result
diagnost
techniqu
percentag
infect
cell
liquid
obtain
bal
ie
valu
direct
examin
clinic
practic
time
direct
examin
pulmonari
secret
import
issu
sinc
correspond
time
differenti
infect
noninfect
patient
decis
treat
choic
initi
antimicrobi
therapi
author
confirm
strong
relationship
percentag
infect
cell
result
quantit
cultur
bal
also
found
two
factor
neg
associ
percentag
infect
cell
durat
mv
onset
vap
day
day
day
mv
ongo
use
antibiot
suggest
diagnost
criteria
analyz
caution
patient
receiv
prior
antibiot
therapi
clinic
suspicion
lateonset
vap
schurink
et
al
examin
accuraci
cpi
diagnos
vap
evalu
interoberv
variabl
calcul
compar
score
slightli
modifi
cpi
result
quantit
cultur
bal
patient
suspect
vap
diagnosi
vap
base
posit
bal
quantit
cultur
growth
cfuml
patient
cpi
calcul
two
investig
vap
diagnos
patient
use
cpi
higher
diagnos
vap
sensit
score
specif
cutoff
point
diagnost
valu
lower
sensit
specif
addit
major
limit
identifi
author
compromis
wide
use
cpi
clinic
practic
sinc
level
agreement
observ
measur
individu
cpi
vs
poor
conclud
low
specif
sensit
cpi
combin
consider
interobserv
variabl
permit
base
diagnost
strategi
score
luyt
et
al
confirm
observ
retrospect
cohort
studi
conduct
patient
includ
invas
strategi
group
french
multicent
random
trial
compar
two
strategi
invas
vs
clinic
manag
patient
suspect
vap
cpi
calcul
retrospect
data
collect
initi
studi
day
compar
patient
bacteriolog
confirm
vap
day
cpi
similar
two
group
vs
without
vap
respect
ns
day
patient
cpi
higher
base
algorithm
describ
singh
et
al
patient
would
requir
prolong
antimicrobi
therapi
compar
strategi
base
bronchoscopi
patient
without
bacteriolog
confirm
vap
would
unnecessarili
treat
patient
vap
would
receiv
antibiot
day
total
patient
incorrectli
manag
year
clinic
evalu
includ
temperatur
macroscop
aspect
tracheal
secret
leukocytosi
chest
radiographi
repeatedli
identifi
least
nonoptim
way
diagnos
pneumonia
patient
treat
mv
cpi
quantif
clinic
evalu
inde
constitut
signific
progress
particularli
includ
manag
algorithm
indic
yu
singh
editori
use
algorithm
base
cpi
result
limit
number
durat
antibiot
reduc
incid
infect
due
multiresist
bacteria
shorten
durat
stay
lower
mortal
rate
therefor
possibl
reduc
antibiot
use
without
deleteri
consequ
mvtreat
patient
treat
clinic
sign
suggest
develop
vap
furthermor
author
clearli
state
excess
broadspectrum
therapi
lead
greater
emerg
multiplyresist
organ
increas
mortal
morbid
limit
use
antibiot
patient
cpi
lower
import
first
step
revisit
strategi
yu
singh
report
import
data
concern
strategi
year
follow
implement
singh
protocol
experienc
singl
case
patient
invas
infect
lead
death
patient
cpi
receiv
day
monotherapi
thu
relev
question
patient
develop
vap
patient
requir
antibiot
answer
question
possibl
propos
least
two
new
random
trial
first
accord
author
comparison
shortcours
monotherapi
vs
antibiot
patient
low
cpi
second
comparison
singh
protocol
bacteriolog
strategi
alreadi
evidenc
superior
classic
clinic
strategi
adequaci
initi
antibiot
therapi
recogn
major
prognost
factor
patient
vap
statement
seem
obviou
also
rational
give
broadspectrum
antibiot
patient
clinic
suspicion
vap
ignor
risk
emerg
resist
morbid
mortal
associ
absenc
control
antibiot
prescript
thu
relationship
appropri
treatment
outcom
need
clarifi
clec
h
et
al
conduct
studi
patient
bacteriolog
confirm
vap
test
hypothesi
link
adequaci
treatment
sever
ill
vap
onset
outcom
rate
adequ
antibiot
therapi
day
day
signific
differ
mortal
observ
without
adequ
initi
treatment
entir
popul
howev
patient
low
sever
level
defin
logist
organ
dysfunct
score
inadequ
therapi
clearli
associ
higher
icu
mortal
vs
patient
appropri
treat
pend
confirmatori
studi
result
potenti
major
impact
manag
patient
suspect
vap
appropri
choic
antibiot
particular
import
group
patient
low
sever
level
time
onset
clinic
sign
infect
reasonn
perform
accur
bacteriolog
investig
popul
guid
choic
initi
treatment
develop
correct
evalu
new
antibiot
one
cornerston
improv
therapeut
manag
patient
vap
one
current
increas
difficulti
treatment
infect
due
multiresist
bacteria
pseudomona
aeruginosa
acinetobact
spp
stenotrophomona
maltophilia
blactamas
secretor
enterobacteriacea
methicillinresist
staphylococcu
aureu
mrsa
date
treatment
mrsa
base
use
glycopeptid
linezolid
new
oxazolidinon
potenti
altern
vancomycin
treatment
sever
infect
due
mrsa
kollef
et
al
report
result
retrospect
analysi
subgroup
patient
enrol
two
random
doubleblind
trial
compar
mg
linezolid
g
vancomycin
everi
h
among
patient
suspect
gramposit
vap
vap
due
mrsa
subgroup
clinic
cure
rate
linezolid
vs
vancomycin
bacteri
erad
rate
vs
surviv
rate
vs
logist
regress
analysi
identifi
linezolid
one
independ
factor
associ
surviv
patient
mrsa
vap
apach
ii
score
less
presenc
pleural
effus
absenc
bacteremia
editori
ioana
lode
suggest
linezolid
may
alreadi
better
choic
vancomycin
vap
due
mrsa
major
reason
vancomycin
modest
drug
treatment
lung
infect
due
predominantli
extrem
poor
penetr
vancomycin
epitheli
line
fluid
frequent
inadequ
serum
level
howev
linezolidresist
strain
aureu
alreadi
report
unit
state
unit
kingdom
conclus
author
recommend
linezolid
use
caution
b
parallel
strategi
antibiot
rotat
restrict
use
antibiot
hygien
measur
cohort
adapt
diminish
antibioticselect
pressur
decreas
infect
resist
aureu
design
strategi
prevent
vap
vall
et
al
conduct
studi
identifi
rout
pattern
colon
p
aeruginosa
ninetyeight
intub
patient
ventil
longer
day
investig
author
collect
sampl
tap
water
room
stomach
oropharynx
subglott
secret
trachea
rectum
time
intub
three
time
per
week
observ
colon
patient
tracheal
colon
ten
patient
tracheal
colon
intub
four
develop
vap
p
aeruginosa
isol
sampl
room
tap
water
howev
identifi
pulsotyp
rare
associ
vap
author
conclud
colon
p
aeruginosa
endogen
exogen
consequ
suggest
combin
prophylact
measur
avoid
airway
colon
infect
control
measur
reduc
crosscontamin
subglott
suction
semirecub
posit
propos
prevent
vap
girou
et
al
design
random
trial
evalu
impact
two
measur
tracheal
colon
patient
receiv
longterm
mv
oropharyng
tracheal
secret
collect
daili
sampl
eight
patient
suction
group
ten
patient
control
group
compar
patient
receiv
measur
patient
receiv
standard
care
supin
posit
author
identifi
differ
bacteri
count
trachea
log
cfuml
suction
group
vs
log
cfuml
control
group
colon
day
vs
respect
daili
bacteri
count
oropharynx
trachea
vap
rate
similar
group
conclud
continu
subglott
suction
semirecub
posit
reduc
tracheal
colon
longterm
mv
patient
true
impact
prophylact
measur
need
evalu
precis
contrast
communityacquir
pneumonia
lung
inflammatori
respons
poorli
investig
patient
vap
millo
et
al
examin
whether
cytokin
concentr
chang
lung
patient
vap
investig
lung
use
nondirect
bronchial
lavag
perform
serial
cytokin
cytokin
inhibitor
measur
patient
vap
patient
without
vap
observ
modif
plasma
concentr
cytokin
cytokin
inhibitor
nondirect
bronchial
lavag
fluid
concentr
tumor
necrosi
factor
tumor
necrosi
factor
receptor
interleukin
b
increas
significantli
patient
vap
author
conclud
cytokin
cytokin
inhibitor
product
compartment
lung
patient
develop
vap
elsolh
et
al
evalu
impact
inadequ
antimicrobi
therapi
procoagul
fibrinolyt
activ
patient
bacteriolog
confirm
vap
control
patient
treat
mv
seven
patient
treat
appropri
thrombinantithrombin
complex
prothrombin
activ
fragment
plasminogen
activ
inhibitor
type
level
higher
receiv
adequ
treatment
despit
antibiot
adjust
day
thrombinantithrombin
complex
level
remain
elev
correl
pf
ratio
procoagul
activ
accompani
local
depress
fibrinolyt
capac
correl
found
bacteri
burden
homeostat
derang
author
suggest
lung
inflammatori
respons
patient
inadequ
treat
vap
induc
local
procoagul
activ
associ
hypoxemia
